Alpha-1-Proteinase Inhibitor (Human)
(Alpha-1-PI)
Alpha-1-Proteinase Inhibitor (Human) (Prolastin)
Alpha-1-PI (Prolastin)
Alpha-1-Proteinase inhibitor
( AL-fah-1- PROH-tee-in-ayz)
Pregnancy Category: C Prolastin (Rx)

Classification: Alpha-1-proteinase inhibitor

Action/Kinetics: Alpha-1-PI is the enzyme that is deficient in alpha-1-antitrypsin disease. This disease causes a progressive breakdown of elastin tissues in the alveoli, resulting in emphysema. Often fatal, alpha-1-antitrypsin disease is usually manifested in the third and fourth decades of life. Prolastin is a sterile, lyophilized product obtained from pooled human plasma that is nonreactive for the HIV antibody and the hepatitis B surface antigen. t 1/2: 4.5 days. Therapeutic serum levels: Approximately 80 mg/dL, although such levels may not reflect actual functional alpha-1-PI levels.

Uses: Panacinar emphysema due to congenital alpha-1-proteinase deficiency.

Contraindications: Clients with PiMZ or PiMS phenotypes of alpha-1-antitrypsin deficiency.

Special Concerns: Use with caution in clients at risk for circulatory overload. Safety and efficacy for use in children not determined.

Side Effects: Although precautions are taken during the manufacture of this product, it is possible that hepatitis and other infectious viruses may be present. Miscellaneous: Delayed fever up to 12 hr following treatment, dizziness, lightheadedness, mild transient leukocytosis.

How Supplied: Powder for injection: 20 mg/mL after reconstitution

Dosage
?IV Only Panacinar emphysema.
Adults: 60 mg/kg each week at a rate of 0.08 mL/kg/min (or greater).